Diasorin SpA

DIA: XMIL (ITA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
€176.00RqtshCzzbdplc

Top-Line Growth for Narrow-Moat DiaSorin Still Driven by COVID-19 Testing; Ends Year With Momentum

Narrow-Moat DiaSorin reported another strong quarter to end 2020, with full-year sales growth of 27% on a constant-exchange basis and profit of nearly EUR 250 million, a significant increase over the EUR 175 million reported last year. We are leaving our EUR 87 fair value estimate unchanged, though we may increase our fair value estimate after reviewing our future estimates.

Sponsor Center